A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
Abstract CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-024-01635-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147551494930432 |
|---|---|
| author | Xiumin Li Xudong Wang Hao Wang Donghua Zuo Jianpo Xu Yixuan Feng Dixuan Xue Li Zhang Lin Lin Jin Zhang |
| author_facet | Xiumin Li Xudong Wang Hao Wang Donghua Zuo Jianpo Xu Yixuan Feng Dixuan Xue Li Zhang Lin Lin Jin Zhang |
| author_sort | Xiumin Li |
| collection | DOAJ |
| description | Abstract CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients’ primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously. Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors. |
| format | Article |
| id | doaj-art-f50b99d10a16488b87be21e554441193 |
| institution | Kabale University |
| issn | 1756-8722 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-f50b99d10a16488b87be21e5544411932024-12-01T12:41:12ZengBMCJournal of Hematology & Oncology1756-87222024-11-011711510.1186/s13045-024-01635-5A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapyXiumin Li0Xudong Wang1Hao Wang2Donghua Zuo3Jianpo Xu4Yixuan Feng5Dixuan Xue6Li Zhang7Lin Lin8Jin Zhang9The First Department of Gynecological Oncology, Linyi Cancer HospitalLiangzhu Laboratory, Zhejiang UniversityCellOrigin Biotech (Hangzhou) Co., LtdThe First Department of Gynecological Oncology, Linyi Cancer HospitalCellOrigin Biotech (Hangzhou) Co., LtdCellOrigin Biotech (Hangzhou) Co., LtdLiangzhu Laboratory, Zhejiang UniversityCellOrigin Biotech (Hangzhou) Co., LtdCellOrigin Biotech (Hangzhou) Co., LtdLiangzhu Laboratory, Zhejiang UniversityAbstract CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients’ primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously. Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors.https://doi.org/10.1186/s13045-024-01635-5Chimera antigen receptor (CAR)Autologous macrophageMesothelinOvarian cancer |
| spellingShingle | Xiumin Li Xudong Wang Hao Wang Donghua Zuo Jianpo Xu Yixuan Feng Dixuan Xue Li Zhang Lin Lin Jin Zhang A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy Journal of Hematology & Oncology Chimera antigen receptor (CAR) Autologous macrophage Mesothelin Ovarian cancer |
| title | A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy |
| title_full | A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy |
| title_fullStr | A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy |
| title_full_unstemmed | A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy |
| title_short | A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy |
| title_sort | clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy |
| topic | Chimera antigen receptor (CAR) Autologous macrophage Mesothelin Ovarian cancer |
| url | https://doi.org/10.1186/s13045-024-01635-5 |
| work_keys_str_mv | AT xiuminli aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT xudongwang aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT haowang aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT donghuazuo aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT jianpoxu aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT yixuanfeng aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT dixuanxue aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT lizhang aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT linlin aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT jinzhang aclinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT xiuminli clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT xudongwang clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT haowang clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT donghuazuo clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT jianpoxu clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT yixuanfeng clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT dixuanxue clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT lizhang clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT linlin clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy AT jinzhang clinicalstudyofautologouschimericantigenreceptormacrophagetargetingmesothelinshowssafetyinovariancancertherapy |